Online now: Intra-and extrahepatic inflammation in MASH is driven by various hits such as lipotoxicity, the gut microbiome, and proinflammatory diets. Inflammation contributes to hepatic and systemic complications, including cardiovascular diseases. Beneficial drugs in MASH might target metabolic and inflammatory pathways.
Inflammation is a key driver of this disease, and effective future therapies might have to target metabolic and inflammatory pathways.
Assessment of inflammation, i.e., MASH in humans, is still challenging as it might appear intermittently during the clinical course and could be missed by liver biopsy. Future non-invasive strategies assessing the liver’s inflammatory burden are eagerly awaited.






